✓Verified Issuer · SEBI Listed
Anglo-French Drugs & Industries Ltd Unlisted Shares
Anglo-French Drugs & Industries Ltd Unlisted Shares Share Price
Industry manufacturingSector pharmaDepository NSDL, CDSL
52W High
₹3,600.00
52W Low
₹1,669.50
1Y Return
-53.6%
Overview
About The Company
Deep Dive
Anglo-French Drugs & Industries Ltd Unlisted Shares Unlisted Shares
Financials · IPO timeline · Growth projects
Anglo-French Drugs & Industries Limited (AFDIL) operates as a pharmaceutical company. The Company manufactures and processes vitamins, anti-epileptics, anti-oxidants, sleep inducing agents, cold and cough preparations, protein food supplements, digestive enzymes, and calcium supplements. AFDIL serves clients worldwide.
Quality At AFDIL, Quality is of foremost concern. In nearly 100 years of operations, we have continuously remained one of India’s most trustworthy manufacturers. Our commitment to quality is managed by current and validated technology, the best resources, effective cGMP, efficient and trained personnel, excellent production design and continuous in-process monitoring.
Strong
Market Position
Consistent
YoY Growth
Experienced
Management
Fundamentals
Key Indicators
A snapshot of Anglo-French Drugs & Industries Ltd Unlisted Shares's financial health, valuation multiples and capital efficiency at a glance.
Current Share Price₹1,669.50
Face Value / Share₹10.00
Book Value / Share₹1,134.55
Price to Earning (PE)58.06
Price / Sales3.36
Price / Book3.17
Outstanding Shares0.01Cr
Market Cap₹39.60Cr
Debt / Equity0.50
Dividend / Share₹1.50
Dividend %0.20%
Return on Total Assets3.7%%
Return on Equity5.7%%
Working Capital Return7.2%%
Anglo-French Drugs & Industries Ltd Unlisted SharesNSDL, CDSL Unlisted Shares
₹1,670
Estimated total₹16,695
Settled in T+2 days · KYC verified dealers
Performance
Pricing Trends
6-Month Movement
₹1,669.50↗ +0.00 (+0.00%)
Financials
Financial Performance
| Indicators | 2025 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 118.0 | 166.1 | 154.8 | 131.7 | 129.8 | 112.4 |
| Expense | 105.0 | 156.7 | 137.4 | 117.8 | 122.2 | 119.2 |
| EBITDA | 13.0 | 9.4 | 17.4 | 13.9 | 7.6 | -6.8 |
| Other Cost | 5.1 | 7.2 | 7.8 | 10.3 | 8.5 | 6.1 |
| Profit Before Taxes | 7.9 | 2.2 | 9.6 | 3.6 | -0.9 | -12.9 |
| Tax Expense | 0.7 | 0.4 | 2.1 | 0.6 | 0.0 | -1.7 |
| Profit after Taxes | 7.2 | 1.9 | 7.5 | 3.1 | -0.9 | -11.2 |
| Other Income (Exp.) | -0.1 | 0.0 | -0.3 | -0.2 | 0.4 | 0.2 |
| Income (Net of Taxes) | 7.1 | 1.9 | 7.5 | 3.1 | -0.8 | -11.2 |
| Outstanding Share | 0.11 | 0.19 | 0.13 | 0.12 | 0.12 | 0.12 |
| Earning per Share (₹) | 62.00 | 16.00 | 5.80 | 2.70 | -0.70 | -9.70 |
| Revenue Growth % | -29.0% | 7.3% | 17.5% | 1.5% | 15.5% | — |
| EBITDA Margin % | 11.0% | 5.7% | 11.2% | 10.6% | 5.9% | -6.0% |
| Net Margin % | 6.0% | 1.1% | 4.8% | 2.4% | -0.6% | -10.0% |
| EPS Growth % | 287.5% | 175.9% | 114.8% | -485.7% | -92.8% | — |
Corporate
Registered Address
#
ISIN
INE570E01016
§
PAN
AAACA9756E
Address
No. 41, 3rd Cross, 5th Block, Rajajinagar, Bengaluru – 560 010, Karnataka , India.
RTA
N/A
Leadership
Management Team
MA
Mr. Abhay Kanoria
Chairman & Managing Director
MH
Mr. Harshwardhan Murarka
Chief Financial Officer
MD
Mrs. Deepa Ramachandran
Company Secretary
Reports
Download Financial Results
📄Annual Report 2022
▼📅Select Year
▼Press


In The News

ET↗
Lupin completes acquisition of portfolio of brands from Anglo-French Drugs & Industries
Aug 26, 2025
Learn more →
DRIVE↗
Anglo French Drugs and Industries Ltd outcome of the board meeting held on 17th January 2022
Jul 29, 2025
Learn more →
DRIVE↗
Extract of un-audited financial results for the Quarter Ended 30th september, 2021
Jul 29, 2025
Learn more →Top Unlisted companies
Help
Frequently Asked Questions
?
Still have questions?
Our expert team typically responds within 30 minutes during market hours.
Due to past performance and potential to grow, investment in Anglo French Drugs and Ind. Ltd unlisted shares is a wise choice. At Stockify, you can easily buy and sell unlisted shares of Anglo French Drugs and Ind. Ltd. You just need to connect with our expert share brokers, and they will help you throughout the process.







